Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ross Stores, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Ross Stores, Inc. trades at $248.31 (market cap $80.78B). The key difference: Ross Stores, Inc. is far larger — about 2.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Ross Stores, Inc. pays a 0.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ROST | |
|---|---|---|
Market Cap | $29.60B | $80.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $255.23 |
52-Week Low | $205.48 | $144.67 |
Enterprise Value | $27.56B | $81.37B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Ross Stores (ROST) trades at $248.48, down 2.49% on the day, with a bullish technical outlook supported by moving averages and strong support near $247. The company reported robust earnings beats in recent quarters, with Q2 2026 results expected on August 20, 2026. Revenue grew to $21.13B in 2025, and net income reached $2.09B, reflecting a 9.74% margin. Expansion continues with 47 new stores opened in mid-2026, signaling growth momentum.
ROST offers solid growth potential with high ROE of 38.98% and analyst consensus favoring a buy rating (63.83% of 47 analysts), targeting $259.00. Risks include elevated P/E of 35.17 and sensitivity to consumer spending shifts. The stock's proximity to its 52-week high suggests cautious optimism, but execution on store expansions and margin maintenance are key for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
